Acute T lymphoid and megakaryoblastic bi-lineal leukemia in a child

Upendra Srinivas1, Renu Saxena, Sameer Bakhshi

  • 1Departments of Hematology and Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110 029, India.

Indian Pediatrics
|August 9, 2007
PubMed

Insights

A rare case of childhood leukemia presented with two distinct cell types, T-lymphoid and megakaryocytic, in the bone marrow. This bi-lineal leukemia was refractory to treatment, highlighting a unique diagnostic and therapeutic challenge.

Area of Science:

  • Pediatric Hematology Oncology
  • Molecular Biology
  • Immunophenotyping

Background:

  • Childhood leukemia is a significant health concern, with various subtypes requiring specific treatment protocols.
  • Accurate diagnosis of leukemia subtypes is crucial for effective therapeutic strategies.
  • Bi-lineal leukemia, involving two distinct cell lineages, is exceptionally rare in pediatric patients.

Observation:

  • A 1.5-year-old boy presented with clinical signs including fever, anemia, petechial rash, and hepatosplenomegaly.
  • Bone marrow examination revealed two morphologically distinct blast populations: small and large.
  • Immunophenotyping confirmed the presence of both T-lymphoid and megakaryocytic lineages within the blast population.

Findings:

  • The patient exhibited a rare combination of bi-lineal leukemia, co-expressing markers for T-lymphoid and megakaryocytic differentiation.
  • The leukemia was refractory to standard therapeutic interventions.
  • Morphological and immunophenotypic analysis confirmed the dual lineage nature of the blasts.

Implications:

  • This case underscores the importance of comprehensive diagnostic evaluation, including immunophenotyping, for complex pediatric leukemia presentations.
  • The refractoriness to therapy suggests the need for novel therapeutic approaches for rare bi-lineal leukemias.
  • Further research into the pathogenesis and treatment of mixed-lineage leukemias is warranted to improve patient outcomes.